Post Operative Nausea And Vomiting - Pipeline Review, H2 2016

  • ID: 3984510
  • Report
  • 50 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acacia Pharma Ltd
  • Camurus AB
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics Inc
  • Suda Ltd
  • MORE
Post Operative Nausea And Vomiting - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides an overview of the Post Operative Nausea And Vomiting (Gastrointestinal) pipeline landscape.

Postoperative nausea and vomiting (PONV) is one of the commonest complaints following anaesthesia, and can result in morbidity like wound dehiscence, bleeding, pulmonary aspiration of gastric contents, fluid and electrolyte disturbances, delayed hospital discharge, unexpected hospital admission, and decreased patient satisfaction. The thorough understanding of the mechanism of nausea and vomiting and a careful assessment of risk factors provide a rationale for appropriate management of PONV. This multimodal PONV management approach includes use of: (i) multiple different antiemetic medications (double or triple combination antiemetic therapy acting at different neuroreceptor sites); (ii) less emetogenic anaesthesia techniques; (iii) adequate intravenous hydration; and (iv) adequate pain control.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Operative Nausea And Vomiting (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Post Operative Nausea And Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 2, 1, 1 and 1 respectively.Post Operative Nausea And Vomiting.

Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Operative Nausea And Vomiting (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Post Operative Nausea And Vomiting (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Operative Nausea And Vomiting (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Operative Nausea And Vomiting (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Operative Nausea And Vomiting (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Operative Nausea And Vomiting (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Operative Nausea And Vomiting (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acacia Pharma Ltd
  • Camurus AB
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics Inc
  • Suda Ltd
  • MORE
List of Tables

List of Figures

Introduction

Post Operative Nausea And Vomiting Overview

Therapeutics Development

Pipeline Products for Post Operative Nausea And Vomiting - Overview

Post Operative Nausea And Vomiting - Therapeutics under Development by Companies

Post Operative Nausea And Vomiting - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Unknown Stage Products

Post Operative Nausea And Vomiting - Products under Development by Companies

Post Operative Nausea And Vomiting - Companies Involved in Therapeutics Development

Acacia Pharma Ltd

Camurus AB

GW Pharmaceuticals Plc

INSYS Therapeutics Inc

Suda Ltd

Post Operative Nausea And Vomiting - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(buprenorphine hydrochloride + granisetron hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amisulpride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nabiximols - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post Operative Nausea And Vomiting - Dormant Projects

Post Operative Nausea And Vomiting - Discontinued Products

Post Operative Nausea And Vomiting - Product Development Milestones

Featured News & Press Releases

Aug 12, 2016: Positive Results From Pivotal Phase 3 Trial of BAREMSIS For The Treatment of PONV

Mar 21, 2016: Initiation of Second Pivotal Phase 3 Treatment Trial with BAREMSIS (APD421) in PONV

Jan 05, 2016: Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In PONV

Apr 21, 2015: Phase 3 Combination Prophylaxis Study Initiated With APD421 In PONV

Oct 07, 2014: Acacia Pharma Announces Positive Phase 3 Results For APD421 in Post-Operative Nausea & Vomiting

Sep 17, 2013: Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting

May 28, 2012: Acacia Pharma Announces Positive Results For APD421 In Post-Operative Nausea & Vomiting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Post Operative Nausea And Vomiting - Pipeline by Acacia Pharma Ltd, H2 2016

Post Operative Nausea And Vomiting - Pipeline by Camurus AB, H2 2016

Post Operative Nausea And Vomiting - Pipeline by GW Pharmaceuticals Plc, H2 2016

Post Operative Nausea And Vomiting - Pipeline by INSYS Therapeutics Inc, H2 2016

Post Operative Nausea And Vomiting - Pipeline by Suda Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Post Operative Nausea And Vomiting - Dormant Projects, H2 2016

Post Operative Nausea And Vomiting - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acacia Pharma Ltd
  • Camurus AB
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics Inc
  • Suda Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll